SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.

Autor: Hoff FW; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Goksu SY; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Premnath N; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Patel PA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Ikpefan R; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Kaur G; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Vusirikala M; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Bat T; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Chen W; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX., Geethakumari PR; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Anderson LD Jr; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Awan FT; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Collins RH; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Weinberg OK; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX., Muthukumar A; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX., Chung SS; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Madanat YF; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA. yazan.madanat@utsouthwestern.edu.
Jazyk: angličtina
Zdroj: Acta medica academica [Acta Med Acad] 2023 Apr; Vol. 52 (1), pp. 30-36.
DOI: 10.5644/ama2006-124.399
Abstrakt: Objective: Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.
Methods: Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.
Results: Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.
Conclusion: Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.
(Copyright © Hoff et al. This article is available under a Creative Commons License (Attribution 4.0 International).)
Databáze: MEDLINE
Externí odkaz: